Regeneron Pharmaceuticals, Inc. (REGN) Tops Q4 EPS by 36c

February 14, 2013 6:36 AM EST Send to a Friend
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q4 EPS of $1.47, $0.36 better than the analyst estimate of $1.11. Revenue for the quarter came in at $415 million versus the consensus estimate of $392.64 million.

For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings

Add Your Comment